EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2‐mediated glycolysis

Han Xu iD, Longzhi Li, Bing Dong, Ji Lu, Kun Zhou, Xiaoxing Yin, Huizhen Sun iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Han Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Jing'an District Center Hospital of Shanghai, Shanghai, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ample evidence reveals that glycolysis is crucial to tumor progression; however, the underlying mechanism of its drug resistance is still worth being further explored. TRAF6, an E3 ubiquitin ligase, is well recognized to overexpress in various types of cancer, which predicts a poor prognosis. In our study, we discovered that TRAF6 was expressed more significantly in the case of triple‐negative breast cancer (TNBC) than in other of breast cancers, promoting chemoresistance to paclitaxel; that inhibited TRAF6 expression in the chemoresistant TNBC (TNBC‐CR) cells enhanced the sensitivity by decreasing glucose uptake and lactate production; that TRAF6 regulated glycolysis and facilitated chemoresistance via binding directly to PKM2; and that overexpressing PKM2 in the TNBC‐CR cells with TRAF6 knocked down regained significantly TRAF6‐dependent drug resistance and glycolysis. Additionally, we verified that TRAF6 could facilitate PKM2‐mediated glycolysis and chemoresistance in animal models and clinical tumor tissues. Thus, we identified the novel function of TRAF6 to promote glycolysis and drug resistance in TNBC with the regulation of PKM2, which could provide a potential molecular target for TNBC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHumansAnimalsPaclitaxelTNF Receptor-Associated Factor 6Drug Resistance, NeoplasmCell Line, TumorGlycolysisCell ProliferationGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

PKM2TRAF6breast cancerchemoresistanceglycolysis

Substanzen

PaclitaxelTNF Receptor-Associated Factor 6

Autor:innen und Institutionen

  • Department of General Surgery, Jing'an District Center Hospital of Shanghai, Shanghai, China.
  • Department of Obstetrics and Gynecology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.

ORCID-Profile: Han Xu, Huizhen Sun

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, H., Li, L., Dong, B., Lu, J., Zhou, K., Yin, X., & Sun, H. (2023). TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2‐mediated glycolysis. Cancer Medicine. https://doi.org/10.1002/cam4.6552

Vancouver

Xu H, Li L, Dong B, Lu J, Zhou K, Yin X, et al. TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2‐mediated glycolysis. Cancer Medicine. 2023. doi:10.1002/cam4.6552

BibTeX
@article{Xu2023,
  author = {Xu, Han and Li, Longzhi and Dong, Bing and Lu, Ji and Zhou, Kun and Yin, Xiaoxing and Sun, Huizhen},
  title = {TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2‐mediated glycolysis},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6552}
}
Kostenlos starten →